Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Kidney Transplant Rejection: Effect on Donor-derived Cell-free DNA and C-X-C Motif Chemokine Ligand 10

Background. Targeting interleukin-6 (IL-6) was shown to counteract donor-specific antibody production and antibody-mediated rejection (AMR) activity. It is not known whether, or to what extent, IL-6 antagonism modulates biomarkers indicative of tissue damage (donor-derived cell-free DNA [dd-cfDNA])...

Full description

Bibliographic Details
Main Authors: Katharina A. Mayer, MD, Konstantin Doberer, MD, Philip F. Halloran, MD, PhD, Klemens Budde, MD, Susanne Haindl, BSc, Jakob Mühlbacher, MD, PhD, Farsad Eskandary, MD, PhD, Thierry Viard, PhD, Silvia Casas, PhD, Bernd Jilma, MD, Georg A. Böhmig, MD
Format: Article
Language:English
Published: Wolters Kluwer 2022-12-01
Series:Transplantation Direct
Online Access:http://journals.lww.com/transplantationdirect/fulltext/10.1097/TXD.0000000000001406

Similar Items